Sam Brusco, Associate Editor08.02.22
Insulet has announced its Omnipod 5 automated insulin delivery (AID) system is now fully available via retail pharmacy channels for those six and over with type 1 diabetes.
“With the significant demand for our tubeless AID system and impressive clinical outcomes, we continue to expand access to Omnipod 5 and provide a best-in-class experience to more people with type 1 diabetes,” Bret Christensen, Insulet’s chief commercial officer told the press. “Through our team’s learnings from the limited market release, we have met our timeframe and goals. We are thrilled to announce that Omnipod 5 is now fully available through retail, specialty, and mail-order pharmacies to anyone with a prescription and coverage.”
Omnipod 5 integrates with the Dexcom 6 CGM system to help protect against high and low glucose levels. The tubeless AID can be operated via smartphone or separate controller that’s provided to every customer. Insulet is expanding its list of compatible smartphones to make the option further available.
“Omnipod 5 has been such a life-changing technology. My patients and I have seen significant improvement of their time in range with no overnight lows and much less work required,” said Dr. Anita Swamy, Assistant Professor of Pediatrics, Northwestern Feinberg School of Medicine; Associate Clinician, Pediatric Endocrinology, Ann and Robert H. Lurie Children’s Hospital of Chicago; Medical Director, Chicago Children’s Diabetes Center. “It has given parents and other caregivers more peace of mind, especially overnight, and that’s priceless. People no longer have to make trade-offs between outcomes and a better lifestyle fit because it’s a tubeless AID.” She continued, “Many have told me that they have been extremely happy with Omnipod 5 and are feeling a new sense of freedom. I can see why there has been tremendous demand for this product!”
According to the company, Omnipod 5 and Omnipod DASH are the only insulin pumps available through pharmacy channels, removing the high upfront cost and four-year lock-in period typical with the traditional Durable Medical Equipment channel.
“With the significant demand for our tubeless AID system and impressive clinical outcomes, we continue to expand access to Omnipod 5 and provide a best-in-class experience to more people with type 1 diabetes,” Bret Christensen, Insulet’s chief commercial officer told the press. “Through our team’s learnings from the limited market release, we have met our timeframe and goals. We are thrilled to announce that Omnipod 5 is now fully available through retail, specialty, and mail-order pharmacies to anyone with a prescription and coverage.”
Omnipod 5 integrates with the Dexcom 6 CGM system to help protect against high and low glucose levels. The tubeless AID can be operated via smartphone or separate controller that’s provided to every customer. Insulet is expanding its list of compatible smartphones to make the option further available.
“Omnipod 5 has been such a life-changing technology. My patients and I have seen significant improvement of their time in range with no overnight lows and much less work required,” said Dr. Anita Swamy, Assistant Professor of Pediatrics, Northwestern Feinberg School of Medicine; Associate Clinician, Pediatric Endocrinology, Ann and Robert H. Lurie Children’s Hospital of Chicago; Medical Director, Chicago Children’s Diabetes Center. “It has given parents and other caregivers more peace of mind, especially overnight, and that’s priceless. People no longer have to make trade-offs between outcomes and a better lifestyle fit because it’s a tubeless AID.” She continued, “Many have told me that they have been extremely happy with Omnipod 5 and are feeling a new sense of freedom. I can see why there has been tremendous demand for this product!”
According to the company, Omnipod 5 and Omnipod DASH are the only insulin pumps available through pharmacy channels, removing the high upfront cost and four-year lock-in period typical with the traditional Durable Medical Equipment channel.
